Comparing two chemotherapies for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial compares two chemotherapy drug combinations (FOLFOX-6 and CAPOX) to see which works better and has fewer side effects for people with colorectal cancer that has spread. It may help you and your doctor choose the best treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 70 years old
- You have colorectal cancer that has spread to other parts of the body (metastatic)
- You had surgery to remove the tumor and are now receiving chemotherapy
- You do not have another cancer besides colorectal cancer
- You have no history of a brain or nerve disorder (like stroke, Parkinson's, or neuropathy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different chemotherapy regimens (FOLFOX8 and mFOLFOX6), each paired with a targeted drug (bevacizumab or cetuximab), to treat colorectal cancer that has spread and cannot be surgically removed. The goal is to find which combination works best as a first treatment.
This trial compares two different chemotherapy combinations, both including a targeted therapy called cetuximab, as a first treatment for people with a specific type of advanced left-sided colon cancer that cannot be surgically removed. The goal is to find out which combination works better.
This trial tests two chemotherapy drugs, capecitabine alone or with oxaliplatin, in people aged 70 or older after surgery for stage III colorectal cancer. The goal is to find out which treatment works better to prevent cancer from coming back.
This trial tests a new drug (RC148) combined with standard chemotherapy as a first treatment for colorectal cancer that has spread or cannot be removed. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a stronger chemo combination (FOLFOXIRI) versus the standard ones (CAPOX or FOLFOX), both followed by chemoradiation, then surgery or a watch-and-wait approach for people with high-risk locally advanced rectal cancer. The goal is to see which approach works better at preventing the cancer from coming back.
This trial tests a modified version of a common chemotherapy combination (capecitabine and oxaliplatin) for people with gastrointestinal cancers who are not expected to be cured. It aims to see if a simpler treatment schedule can be just as effective while reducing side effects.
Hear when a new Metastatic Colorectal Carcinoma (mCRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.